In contrast, mutant p53 variants (e.g., R175H and R273H) can bind to the PPARγ promoter to suppress its transcription, resulting in metabolic dysregulation (e.g., enhanced glycolysis) and deterioration of the inflammatory tumor microenvironment. The gene discussed is TP53; the disease is neoplasm.